Marcus Renner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marcus Renner has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Benedikt Brors
Division of Applied Bioinformatics, The German Cancer Research Center (DKFZ), Heidelberg, Germany
1 shared publication Esteban Czwan
Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
1 shared publicationEva Wardelmann
Institute of Pathology, University Hospital of Cologne, Cologne 50937, Germany
1 shared publicationGunhild Mechtersheimer
Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg 69120, Germany
1 shared publicationPeter Lichter
Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
1 shared publicationPeter Schirmacher
Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg 69120, Germany
1 shared publication
Latest Publications
- 18 July 2012
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (11) , 982-996
MicroRNA profiling of primary high‐grade soft tissue sarcomas
High‐grade soft tissue sarcomas are a heterogeneous and complex group of tumors. MicroRNAs (miRNAs) are considered as attractive candidates that may improve diagnostic, prognostic, and predictive characterization of this group of malignancies. We performed a comprehensive miRNA expression analysis in a series of 76 untreated, primary high‐grade soft tissue sarcomas representing eight subtypes, and in a panel of 15 representative sarcoma cell lines using microarray technology. This screening revealed unique miRNA expression patterns for synovial sarcomas, myxoid liposarcomas, and leiomyosarcomas, and defined unique sets of miRNAs discriminating the different liposarcoma subtypes from non‐neoplastic adipose tissue. The over‐represented miRNAs included members of the miR‐200 family in synovial sarcomas, and the tumor‐associated miR‐9 and miR‐9* in myxoid liposarcomas compared to adipose tissue. Moreover, we found coexpression of 63 miRNAs clustering in a genetically imprinted chromosomal region 14q32.2 separating primary sarcoma samples and sarcoma cell lines into two molecular subgroups. Taken together, our comprehensive miRNA profiling identified a novel set of miRNAs that might contribute to sarcomagenesis and provide a starting point for experimental modulation of relevant targets for new therapeutic strategies in high‐grade sarcomas.
- 18 July 2012
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (11) , 982-996
MicroRNA profiling of primary high‐grade soft tissue sarcomas
High‐grade soft tissue sarcomas are a heterogeneous and complex group of tumors. MicroRNAs (miRNAs) are considered as attractive candidates that may improve diagnostic, prognostic, and predictive characterization of this group of malignancies. We performed a comprehensive miRNA expression analysis in a series of 76 untreated, primary high‐grade soft tissue sarcomas representing eight subtypes, and in a panel of 15 representative sarcoma cell lines using microarray technology. This screening revealed unique miRNA expression patterns for synovial sarcomas, myxoid liposarcomas, and leiomyosarcomas, and defined unique sets of miRNAs discriminating the different liposarcoma subtypes from non‐neoplastic adipose tissue. The over‐represented miRNAs included members of the miR‐200 family in synovial sarcomas, and the tumor‐associated miR‐9 and miR‐9* in myxoid liposarcomas compared to adipose tissue. Moreover, we found coexpression of 63 miRNAs clustering in a genetically imprinted chromosomal region 14q32.2 separating primary sarcoma samples and sarcoma cell lines into two molecular subgroups. Taken together, our comprehensive miRNA profiling identified a novel set of miRNAs that might contribute to sarcomagenesis and provide a starting point for experimental modulation of relevant targets for new therapeutic strategies in high‐grade sarcomas.